Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 3;15(1):55.
doi: 10.1038/s41408-025-01258-0.

Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the Beat AML clinical trial

Fieke W Hoff  1 , Ying Huang  2 , Rina Li Welkie  2 , Ronan T Swords  3 , Elie Traer  3 , Eytan M Stein  4 , Tara L Lin  5 , Prapti A Patel  6 , Robert H Collins Jr  1 , Maria R Baer  7 , Vu H Duong  7 , William G Blum  8 , Martha L Arellano  8 , Wendy Stock  9 , Olatoyosi Odenike  9 , Robert L Redner  10 , Tibor Kovacsovics  11 , Michael W Deininger  12 , Joshua F Zeidner  13 , Rebecca L Olin  14 , Catherine C Smith  14 , James M Foran  15 , Gary J Schiller  16 , Emily K Curran  17 , Kristin L Koenig  2 , Nyla A Heerema  2 , Timothy Chen  2 , Molly Martycz  2 , Mona Stefanos  2 , Sonja G Marcus  18 , Leonard Rosenberg  18 , Brian J Druker  3 , Ross L Levine  4 , Amy Burd  17 , Ashley O Yocum  18 , Uma M Borate  2 , Alice S Mims  2 , John C Byrd  17 , Yazan F Madanat  19
Affiliations

Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the Beat AML clinical trial

Fieke W Hoff et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: WGB has served on advisory boards of AbbVie and Syndax and has research funding from ImmuneOnc, Meryx, and Nkarta. ET has participated in advisory boards and/or consulting for Abbvie, Astellas, Daiichi-Sankyo, Servier, and Rigel. He has received research funding from Prelude Therapeutics, Schrodinger, Incyte, and Astra-Zeneca. EMS has served on the advisory boards of Astellas Pharma, AbbVie, Genentech, Daiichi Sankyo, Novartis, Amgen, Seattle Genetics, Syros Pharmaceuticals, Syndax Pharmaceuticals, Agios Pharmaceuticals, and Celgene. He is an equity holder in Auron Therapeutics. TLL has received research funding from Bio-path Holdings, Astellas Pharma, Celyad, Aptevo Therapeutics, Cleave Biosciences, Ciclomed, Jazz Pharmaceuticals, and Kura Oncology and serves on the advisory board of Servier. PAP has served on the advisory board of Agios Pharmaceuticals and is currently an employee of Servier. MRB has institutional funding from AbbVie, Ascentage, Astellas, Curadev, Gilead, Kura, Takeda. OO has served on the advisory boards of Servier, Rigel, ABBVIE, Incyte, and data safety monitoring board for Treadwell therapeutics. TK has served on advisory boards from Astellas, Rigel, Takeda; has received honoraria/consulting fees from Servier; has received institutional research funds from Abbvie, Gilead, Novartis, Syndax Pharmaceuticals. MWD is a paid consultant for Novartis, Takeda, Blueprint, Incyte, Dava Oncology, CTIBio, Syneos, Cogent, Pfizer, Dispersol. JFZ has received honoraria from advisory boards and/or consultancy from AbbVie, Daiichi Sankyo, Foghorn, Genmab, Gilead, Novartis, Sellas, Servier, Shattuck Labs, Sumitomo Dainippon, and Syndax; has received research funding from AbbVie, Arog, Astex, AstraZeneca, Gilead, Jazz, Loxo, Merck, Newave, Novartis, Sellas, Shattuck Labs, Stemline, Sumitomo Dainippon Pharma, and Zentalis. RLO has received research funds for Cellectis and consulted for Actinium, Astellas, Abbvie, Rigel, Servier. CCS has received research funds from Abbvie, BMS, Erasca, Revolution Medicines, and Zentalis and served on advisory boards for Abbvie, Genentech, and Astellas. GJS has commercial interests in BMS, Amgen, J&J. He has received fees from AbbVie, Agios, Amgen, Astellas, BMS, Incyte, Janssen, Jazz, Karyopharm, Kite, Pharmacyclics, Sanofi/Genzyme, Stemline. He has received research funds from AbbVie, Actinium, Actuate, Arog, Astellas, AltruBio, AVM Bio, BMS/ Celgene, Celator, Constellation, Daiichi-Sankyo, Deciphera, Delta-Fly, Forma, FujiFilm, Gamida, Genentech-Roche, Glycomimetics, Geron, Incyte, Karyopharm, Kiadis, Kite/Gilead, Kura, Marker, Mateon, Onconova, Pfizer, PrECOG, Regimmune, Samus, Sangamo, Sellas, Stemline, Syros, Takeda, Tolero, Trovagene, Agios, Amgen, Jazz, Orca, Ono-UK, Novartis. MS has been a consultant for Eilean Therapeutics. BJD has the following disclosures. SAB: Adela Bio, Aileron Therapeutics (inactive), Therapy Architects/ALLCRON (inactive), Cepheid, Labcorp, Nemucore Medical Innovations, Novartis, RUNX1 Research Program; SAB & Stock: Aptose Biosciences, Blueprint Medicines, Enliven Therapeutics, Iterion Therapeutics, GRAIL, Recludix Pharma; Board of Directors & Stock: Amgen, Vincerx Pharma; Board of Directors: Burroughs Wellcome Fund, CureOne (inactive); Joint Steering Committee: Beat AML LLS; Advisory Committee: Multicancer Early Detection Consortium; Founder: VB Therapeutics; Sponsored Research Agreement: Astra-Zeneca, DELiver Therapeutics, Immunoforge, Terns, Enliven Therapeutics (inactive), Recludix Pharma (inactive); Clinical Trial Funding: Novartis, Astra-Zeneca; Royalties from Patent 6958335 (Novartis exclusive license) and OHSU and Dana-Farber Cancer Institute (one Merck exclusive license, one CytoImage, Inc. exclusive license, one DELiver Therapeutics non-exclusive license, and one Sun Pharma Advanced Research Company non-exclusive license); US Patents 4326534, 6958335, 7416873, 7592142, 10473667, 10664967, 11049247. RLL is on the supervisory board of Qiagen and is a scientific advisor to Imago, Mission Bio, Syndax. Zentalis, Ajax, Bakx, Auron, Prelude, C4 Therapeutics, and Isoplexis for which he receives equity support. RLL receives research support from Ajax and Abbvie and has consulted for Incyte, Janssen, Morphosys, and Novartis. He has received honoraria from Astra Zeneca and Kura for invited lectures and from Gilead for grant reviews. UMB has been a consultant for Genentech, Daiichi Sankyo, Takeda, Pfizer, AbbVie/Genentech, and Novartis. A.S.M. has served on the advisory boards of AbbVie/Genentech, Novartis, Ryvu Therapeutics, Rigel Therapeutics, Treadwell Therapeutics, and Foghorn Therapeutics. JCB is a current equity holder in Vincerx Pharma Inc (a publicly traded company), Eilean Therapeutics, and Kurome Therapeutics. JCB holds membership on the Board of Directors or advisory committees of Vincerx, Newave, Eilean, and Kartos, and Orange Grove Bio, and holds Consultancy, Honoraria from Novartis, Trillium, Astellas, AstraZeneca, Pharmacyclics, and Syndax. YFM has received honoraria/consulting fees from BMS, Kura Oncology, BluePrint Medicines, Geron, OncLive and MD Education, VJHemOnc, and Medscape Live. YFM participated in advisory boards and received honoraria from Sierra Oncology, Stemline Therapeutics, Blueprint Medicines, Morphosys, Taiho Oncology, SOBI, Rigel Pharmaceuticals, Geron, Cogent Biosciences and Novartis. YFM received travel reimbursement from Blueprint Medicines, MD Education, and Morphosys. None of these relationships were related to this work. Ethics approval and consent to participate: This study was approved by the OSU Scientific Review Board and Western IRB centrally. All methods were performed in accordance with the relevant guidelines and regulations. Informed consent was obtained in accordance to the Declaration of Helsinki.

Figures

Fig. 1
Fig. 1. Gene mutation profile in patients 60 years and older with AML.
A Common driver gene mutations present in ≥ 10% of the patients. Gene mutations with any detectable VAF were considered present. B Analysis of variant allele frequencies of the top 10 most frequently mutated genes. The boxplots show the median, 25th and 75th percentiles, minimum, maximum, and outliers. The black dashed line marks an allele frequency of 0.5. C Co-occurrence of molecular markers across molecular subgroups. The number at the top of each column is the number of patients belonged to the subclass. Red and blue highlighted boxes indicate significant (FDR-corrected p < 0.05) co-occurrence (red) or mutual exclusively (blue) between two gene mutations or between gene mutations and recurrent cytogenetic abnormalities. P-values were calculated using the Fisher’s exact test and were corrected for the number of patients with available cytogenetics (n = 926/1023). For example, of the 280 patients with complex karyotype, 213 patients also had a TP53 mutation, while 5 patients had a NPM1 mutation.
See this image and copyright information in PMC

References

    1. 2016–2020 S. Cancer Stat Facts: Leukemia—Acute Myeloid Leukemia (AML) www.seer.cancer.gov. 2024.
    1. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009;361:1058–66. - PMC - PubMed
    1. Cancer Genome Atlas Research N, Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368:2059–74. - PMC - PubMed
    1. Dohner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345–77. - PubMed
    1. Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209–21. - PMC - PubMed